Indisulam

Last updated
Indisulam
Indisulam.svg
Names
Preferred IUPAC name
N1-(3-Chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
Other names
E7070
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
KEGG
PubChem CID
UNII
  • InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
    Key: SETFNECMODOHTO-UHFFFAOYSA-N
  • C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
Properties
C14H12ClN3O4S2
Molar mass 385.84 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Indisulam is a chloroindolyl sulfonamide cell cycle inhibitor that exhibits antitumor activity in vitro and in an animal model. [1] [2] [3] This compound affects cell cycle progression in human tumor cells and is being studied for the treatment of cancers such as melanomas and blood-borne cancers such as leukemia. [4]

References

  1. ↑ Fukuoka K, Usuda J, Iwamoto Y, et al. (2001). "Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells". Invest New Drugs. 19 (3): 219–27. doi:10.1023/A:1010608317361. PMID   11561678. S2CID   26100991.
  2. ↑ Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K (November 2001). "E7070, a Novel Sulphonamide Agent With Potent Antitumour Activity in Vitro and in Vivo". European Journal of Cancer. 37 (17): 2275–82. doi:10.1016/s0959-8049(01)00275-1. PMID   11677118.
  3. ↑ E. Raymond; W.W. ten Bokkel Huinink; J. Taïeb; J.H. Beijnen; S. Faivre; J. WandersM. Ravic; P. Fumoleau; J.P. Armand; J.H.M. Schellens (2002-08-15). "Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer". Journal of Clinical Oncology. 20 (16): 3508–21. doi:10.1200/JCO.2002.09.030. PMID   12177112.
  4. ↑ Rita Assi; Hagop M. Kantarjian; Jorge E. Cortes; Tapan Kadia; Naveen Pemmaraju; Elias J. Jabbour; Nitin Jain; Naval Daver; Taisuke Uehara; Takashi Owa; Gautam Borthakur (2001). "Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)". Blood. 130 (supplement 1).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.